1733 Erratum Erratum identification GPX4 therapeutic target lung adenocarcinoma EGFRTKI resistance Editorial Office Translational Lung Cancer Research Correspondence Editorial Office Translational Lung Cancer Research Email editortlcrorg Submitted Jun 20 2022 Accepted publication Jul 22 2022 doi 1021037tlcr20224 View article httpsdxdoiorg1021037tlcr20224 Erratum Transl Lung Cancer Res 202211786801 This article 1 titled Identification GPX4 therapeutic target lung adenocarcinoma EGFRTKI resistance doi 1021037tlcr22318 unfortunately contains errors Figure 2D Figure 7A The bands KEAP1 Figure 2D 13 Osimertinib Figure 7A Gefitinib The correct Figure 2 Figure 7 Translational Lung Cancer Research All rights reserved Transl Lung Cancer Res 202211817311733 httpsdxdoiorg1021037tlcr20224 1732 Correct Figure 2 Editorial Office Erratum A GPX4 NRF2 KEAP1 FTH1 ACSL4 LPCAT3 10 3 2 1 20 15 10 05 ns 25 20 15 10 05 ns 40 30 20 10 n o s s e r p x e A N R m e v t e l 0R N m al lung Tu m 00 N m al lung Tu m 00 N m al lung Tu m 0 N m al lung Tu m 8 6 4 2 0 Tu m N m al lung B 3 2 1 n o s s e r p x e A N R m e v t e l 0R 15 10 5 n o s s e r p x e A N R m e v t e l 0R GPX4 NRF2 KEAP1 3 3 2 1 0 2 1 0 FTH1 ACSL4 LPCAT3 15 10 5 0 15 10 5 0 15 10 05 00 Tu m N m al lung B2B HBE MRC5 A549 H1299 H1975 H292 HCC827 PC9 H446 H460 H3122 HCC78 C Stage I Stage II Stage III D Patient 1 2 3 4 5 6 7 8 9 10 11 12 N T N T N T N T N T N T N T N T N T N T N T N T 5 C R M 5 7 9 1 H 9 9 2 1 H 2 9 2 H 6 4 4 H 8 7 C C H 0 6 4 H 9 C P E B H B 2 B 7 2 8 C C H 2 2 1 3 H 9 4 5 A GPX4 NRF2 KEAP1 FTH1 ACSL4 LPCAT3 βactin Stage I Stage II Stage III GPX4 NRF2 KEAP1 FTH1 ACSL4 LPCAT3 βactin E 4 X P G r o m u T g n u l l m r o N Translational Lung Cancer Research All rights reserved Transl Lung Cancer Res 202211817311733 httpsdxdoiorg1021037tlcr20224 Translational Lung Cancer Research Vol 11 No 8 August 2022 1733 Correct Figure 7 A y t l b v l l e C D E 100 75 50 25 0 R G 7 2 8 C C H R O 9 C P HCC827GR B PC9OR C Gefitinib IC50 8777 nM RSL3 Gefitinib IC50 2093 nM y t l b v l l e C 100 75 50 25 0 Osimertinib IC50 2327 nM RSL3 Osimertinib IC50 1428 nM 0 10 100 1000 10000 100000 Gefitinib concentration nM 0 10 100 1000 10000 100000 Osimertinib concentration nM Cell mortality 396 605 1448 3474 DMSO Gefitinib 1 μM RSL3 05 μM Gefitinib 1 μM RSL3 05 μM Cell mortality 310 502 1113 2247 DMSO Osimertinib 1 μM RSL3 05 μM Osimertinib 1 μM RSL3 05 μM HCC827GR PC9OR 40 30 20 10 s l l e c I P 0 RSL3 Gefitinib s l l e c I P 30 20 10 0 DMSO Gefitinib 1 μM RSL3 05 μM Gefitinib 1 μM RSL3 05 μM DMSO Osimertinib 1 μM RSL3 05 μM Osimertinib 1 μM RSL3 05 μM 10000 0 5 C I I K T 8000 6000 4000 2000 0 Without RSL3 With RSL3 HCC827GR PC9OR F HCC827GR PC9OR Propidium lodide FL2 RSL3 Osimertinib The authors apologize oversight Click view updated version article Open Access Statement This Open Access article distributed accordance Creative Commons Attribution NonCommercialNoDerivs 40 International License CC BYNCND 40 permits noncommercial replication distribution article strict proviso changes edits original work properly cited including links formal publication relevant DOI license See httpscreativecommonsorglicensesbync nd40 References 1 Zhang C Wang C Yang Z et al Identification GPX4 therapeutic target lung adenocarcinoma EGFRTKI resistance Transl Lung Cancer Res 202211786801 Cite article Editorial Office Erratum identification GPX4 therapeutic target lung adenocarcinoma EGFRTKI resistance Transl Lung Cancer Res 20221181731 1733 doi 1021037tlcr20224 Translational Lung Cancer Research All rights reserved Transl Lung Cancer Res 202211817311733 httpsdxdoiorg1021037tlcr20224